Abstract 143P
Background
The combination of local thermal ablation with immune checkpoint inhibitors perioperatively for small hepatocellular carcinoma (HCC) is yet to be explored. The aim of this phase II trial was to evaluate the safety and tolerability of thermal ablation in combination with tislelizumab, an anti-PD-1 antibody, in patients with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A or B, and to make a preliminary evaluation of the efficacy of this treatment modality.
Methods
This phase II trial (NCT04652440) enrolled newly diagnosed and recurrent HCC patients with 1 or 2 lesions of 2-5 cm in size. This study included two stages. The first stage included 6 patients for dose-limited toxicity (DLT) observation. Only if DLT appeared in < 2 patients, the other 24 patients would be included. Enrolled patients received the first dose of tislelizumab intravenously within 1 day before percutaneous thermal ablation, followed by infusions every 3 weeks for totally 4 doses. The primary endpoints were safety and tolerability. Secondary endpoints included the rate of complete response by first ablation (CR1), local recurrence rate, distant metastasis rate, and 1- and 2-year disease-free survival (DFS) and overall survival (OS) rates.
Results
No DLT occurred in the first 6 patients, and the study completed recruiting a total 30 subjects in July 2023. Twenty-six subjects had already finished their study treatment and were followed regularly. One patient withdrew her informed consent after completion of the ablation and the first dose of study medication. The other 3 were still on tislelizumab therapy. Until the time of data cut-off (July 30, 2023), the most common adverse events were increased alanine aminotransferase (N=15) and aspartate aminotransferase (N=19) on the first day after ablation. The majority recovered after supportive treatment. 10 patients experienced grade 1-2 immune-related adverse events (irAEs), the most common were rash (N=8), pruritus (N=5), and anorexia (N=4). No ≥3 grade irAEs occurred.
Conclusions
Thermal ablation combined with tislelizumab showed acceptable safety and tolerability with no unexpected SAEs observed. Results of efficacy will be disclosed in future.
Clinical trial identification
NCT04652440.
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract